Drugs / ARG1-18,19,20
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03689192 | Dec 2018 → Jan 2022 | breast cancer, colorectal cancer, head and neck squamous cell carcinoma, melanoma +4 | Herlev Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARG1-18,19,20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03689192 ↗ |
| Action | Deplete | “activate ARG1-specific T cells to infiltrate the tumor microenvironment and eliminate ARG1-expressing immunosuppressive cells” NCT03689192 ↗ |
| Modality | Vaccine | “a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51” NCT03689192 ↗ |
| Route | Subcutaneous | “ARG1 vaccinations administered subcutaneously” NCT03689192 ↗ |
| Target | ARG1 | “activate ARG1-specific T cells to infiltrate the tumor microenvironment and eliminate ARG1-expressing immunosuppressive cells” NCT03689192 ↗ |